The NADH/NADPH oxidase system plays a central role in vascular superoxide anion production, which appears to cause coronary endothelial dysfunction. Recently, it has been suggested that the C242T polymorphism of the NADH/NADPH oxidase p22 phox gene can reduce susceptibility to coronary artery disease. We therefore tested whether this polymorphism is associated with an altered endothelium-dependent vasodilator capacity of human coronary arteries in vivo.
Introduction
The endothelium plays an important role in maintaining vascular tone and function, in part by the synthesis and release of vasoactive substances such as nitric oxide [1] . Abnormalities in endothelial function may contribute to the pathogenesis of coronary artery disease [2] and have been shown to precede atherosclerotic lesion development [3] . Endothelial dysfunction of risk-factor-exposed or atherosclerotic vessels appears to be a consequence of excessive production of reactive oxygen species within the vascular wall [4, 5] . Moreover, scavenging of reactive oxygen species by superoxide dismutase has been shown to improve coronary endothelial vasodilation [6] . Recently, the NADH/NADPH oxidase system has been recognized as having an important role in the generation of superoxide anions in endothelial and vascular smooth muscle cells [7, 8] . A very recent and important investigation has shown that a mutation in the gene encoding for p22 phox, one of the electron transfer elements of NADH/NADPH oxidase, may reduce susceptibility to coronary artery disease [9] . Given the observation that alterations of the redox state in the vascular endothelium fundamentally contribute to the impaired endothelium-dependent control of coronary vasomotor tone, we tested the C242T polymorphism of the p22 phox gene to find out whether it is associated with altered endothelium-dependent vasodilator capacity of human coronary arteries in vivo.
Methods

Patient population
Ninety-three patients undergoing routine diagnostic catheterization were studied. Patients with unstable angina, recent myocardial infarction, valvular heart disease, clinical evidence of heart failure or left ventricular hypertrophy were excluded. The following risk factors for coronary heart disease were assessed:
Hypertension was defined as a history of hypertension for >2 years that required the initiation of antihypertensive therapy by the primary physician.
Hypercholesterolaemia was defined as fasting total serum cholesterol values exceeding the 75th percentile adjusted for age and sex.
Smoking was defined as >2 pack-years cigarette smoking immediately before the study. However, all smokers refrained from smoking at least 4 h before examination.
A positive family history for coronary artery disease was defined as evidence of coronary artery disease in a parent or sibling before 60 years of age, such as a history of myocardial infarction, coronary artery bypass surgery, angina pectoris or a pathological exercise tolerance test diagnostic of ischaemia.
Extent of disease was defined as normal (smooth vessels in the entire coronary tree), minimal disease (luminal irregularities <30% focal stenosis in any vessel) or coronary artery disease (significant stenosis >50% in a vessel other than the vessel under study).
Written informed consent was obtained from all patients before the study. The study protocol had been approved by the ethical committee of the University of Freiburg and the University of Frankfurt.
Study design
Vasoactive therapy including calcium channel blockers, angiotensin-converting enzyme inhibitors and longacting nitrates was discontinued at least 24 h before cardiac catheterization. Beta-blockers were discontinued at least 48 h before catheterization. Diagnostic coronary angiography was performed by a standard percutaneous femoral approach using the Judkins technique. The study protocol has been previously described [3] : in brief, flow-dependent dilation was assessed by injection of 7 mg of papaverine or infusion of adenosine (2·4 mg . min 1 over 2 min) into the mid-portion of the left anterior descending artery or the circumflex artery. Nitroglycerine (0·2-0·3 mg) was injected into the ostium of the left main in order to assess the maximal endothelium-independent vasodilator capacity.
Quantitative coronary angiography
Coronary angiography was performed and analysed as previously described [3, 10, 11] . A 6-8 mm proximal vessel segment, exposed to increased flow, but not pharmacological stimulation was measured and a mean diameter for each segment was calculated for assessment of vasomotor responses [12] .
NADH/NADPH oxidase p22 phox polymorphism
Total genomic DNA was extracted from whole blood with a DNA purification kit (Qiagen, Hilden, Germany) and the p22 phox gene was amplified by polymerase chain reaction with sense primer 5 TGCTTGTGGG TAAACCAAGGCCGGTG-3 and antisense primer 5 AACACTGAGGTAAGTGGGGGTGGCTCCTG T-3 (35 cycles with 45 s at 96 C, 1 min at 54 C, 1·5 min at 72 C). Then, the polymerase chain reaction product (348 bp) was digested with Rsa I (AGS, Heidelberg, Germany). Mutation of C<T at nucleoside 242 creates an Rsa I digestion site, whereas the polymerase chain reaction product amplified from the 
Results
The characteristics of the 93 patients are summarized in Table 1 . The distribution of the C242T polymorphism was CC: n=44 (47%), CT: n=38 (41%) and TT: n=11 (12%). Patients with a positive family history for coronary artery disease had a significantly increased frequency of the CC NADH/NADPH oxidase p22 phox genotype, whereas other risk factors for coronary artery disease did not differ between CC versus TC+TT genotypes. Flow-dependent dilation was significantly increased in patients bearing the T allele of the C242T polymorphism (17 10% luminal area change versus 11 9·2%; P=0·007) (Fig. 1a) . In addition, there was a trend towards an increased vasodilator response to nitroglycerin in carriers of the T allele (37 21% versus 30 18%; P=0·07) (Fig. 1b) . However, when flow-dependent dilation is normalized to nitroglycerininduced vasodilation in order to assess the endotheliumdependent component of vasodilation and to account for the slightly reduced dilator response to nitroglycerin, the CC genotype was still associated with endothelial vasodilator function ( Table 2) . By multivariate analysis, the CC p22 phox genotype and the extent of atherosclerosis were the only predictors of impaired flow-dependent dilation ( Table 2 ). The CC genotype is associated with blunted flow-dependent dilation not only in normal, but also in atherosclerotic coronary arteries compared with patients bearing the TT or TC genotype (Fig. 2) . Thus, the CC genotype is associated with a further aggravation of impairment of endothelial vasodilator function in addition to the presence of atherosclerosis.
The blunted flow-dependent dilation in patients bearing the CC genotype was not related to chronic ACE inhibitor use (n=10, P=0·12) or lipid-lowering therapy (n=6, P=0·93).
Discussion
The results of the present study show that the C242T polymorphism of the p22 phox gene is associated with increased endothelium-dependent vasodilator function of epicardial arteries in vivo. These findings not only support a previous report indicating that the p22 phox gene polymorphism may reduce susceptibility to coronary artery disease [9] , but -more importantlypoint towards the functional significance of a polymorphism of a gene related to superoxide anion production in the vascular wall. 
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Vasodilation in response to increased blood flow in conductance vessels was strictly dependent on an intact normally functioning endothelium [13, 14] and is mediated by the signal of shear stress on the endothelial cell layer [15] to release nitric oxide [16] . Enhanced production of reactive oxygen species in the vascular endothelium is a hallmark very early in the atherogenic process, even preceding atherosclerotic lesion formation [17, 18] . There is ample experimental and clinical evidence that increased vascular superoxide production profoundly inhibits endothelium-mediated vasodilator function by direct reaction between NO and O 2 thereby diminishing NO bioactivity [5] . We have previously shown that atherosclerotic coronary vessels exhibit an impaired flowdependent, endothelium-mediated epicardial vasodilator function [12] . The present study extends these findings by revealing that the CC genotype p22 phox polymorphism is independently associated with blunted flow-dependent epicardial vasodilation compared with patients exhibiting C242T polymorphism. Thus, blunted endotheliumdependent dilation observed in carriers of the CC genotype is not secondary to the presence of coronary artery disease. Azumi et al. [19] have recently shown that, as atherosclerosis progresses, the expression of p22 phox in the vascular tissue increases. However, at the moment it is not known whether the accumulation of the p22 phox in the atherosclerotic wall is related to the p22 phox polymorphism.
It is very tempting to speculate whether patients carrying the CC genotype of the C242T polymorphism produce increased vascular O 2 . If they do, this may account for the blunted endothelium-dependent vasodilator function. It should be noted that free radicals have also been shown experimentally to impair vasodilation in response to nitroglycerin [20] , although to a lesser extent than endogenously released NO. In addition, reduced nitroglycerin-induced vasodilation during chronic nitrate therapy is associated with an increase in vascular NADH/NADPH oxidase activity and O 2 production [21] , which can be corrected by liposome-entrapped superoxide dismutase [22] . The results of the present study, indicating a trend towards an impaired coronary arterial dilator response to nitroglycerin in patients carrying the CC genotype of the C242T p22 phox gene polymorphism, are compatible with these experimental observations and might provide further support for a potential role of increased free radical levels within the vasculature of these patients. However, it is currently unknown whether the C242T mutation of the p22 phox gene modulates the activity and regulation of NADH/NADPH oxidase. Thus, additional studies are needed to provide further evidence of an altered redox state in patients bearing the CC genotype of the p22 phox polymorphism.
Regardless of the mechanisms involved, the present study establishes the C242T polymorphism of the p22 phox gene as an important determinant of coronary endothelial vasodilator function that is independent of the presence or absence of atherosclerotic disease, as well as of coronary risk factors. Since endothelial dysfunction precedes the development of overt atherosclerosis, identification of patients who have a genetically determined increased susceptibility to endothelial dysfunction, due to mutations of genes related to oxidative stress, might be of great advantage for the selective initiation of preventive measures. 
